Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Marinus Pharmaceuticals, Inc. - Common Stock
(NQ:
MRNS
)
0.5500
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Marinus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
November 08, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.
Via
Benzinga
7 Sizzling Stocks That Are Oblivious to the Manic Market
↗
October 20, 2022
While some stocks to buy have performed surprisingly well recently, they remain relatively obscure, providing a contrarian opportunity.
Via
InvestorPlace
BARDA Exercises First Contract Option With Marinus Pharma For Its Epilepsy Candidate
↗
September 22, 2022
Via
Benzinga
Looking Into Marinus Pharmaceuticals's Return On Capital Employed
↗
September 06, 2022
Marinus Pharmaceuticals (NASDAQ:MRNS) brought in sales totaling $1.79 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 103.67%, resulting in a loss of $39.43...
Via
Benzinga
Recap: Marinus Pharma Q2 Earnings
↗
August 11, 2022
Marinus Pharma (NASDAQ:MRNS) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For August 11, 2022
↗
August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Via
Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
↗
July 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 13, 2022
Gainers
Via
Benzinga
Recap: Marinus Pharma Q1 Earnings
↗
May 12, 2022
Marinus Pharma (NASDAQ:MRNS) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Marinus Pharma beat estimated...
Via
Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
↗
May 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
74 Biggest Movers From Yesterday
↗
June 03, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 05, 2022
Via
Benzinga
3 Biotech Stocks Under $10 to Add to Your Buy List
↗
April 26, 2022
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk.
Via
InvestorPlace
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
↗
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
Analyzing Marinus Pharmaceuticals Inc's Short Interest
↗
March 22, 2022
Marinus Pharmaceuticals Inc's (NASDAQ:MRNS) short percent of float has risen 9.74% since its last report. The company recently reported that it has 1.23 million shares sold short...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 21, 2022
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million.
Via
Benzinga
Recap: Marinus Pharmaceuticals Q4 Earnings
↗
March 21, 2022
Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q4 earnings results on Monday, March 21, 2022 at 07:15 AM. Here's what investors need to know about the announcement...
Via
Benzinga
Earnings Scheduled For March 21, 2022
↗
March 21, 2022
Companies Reporting Before The Bell • Marinus Pharmaceuticals (NASDAQ:MRNS) is likely to report quarterly loss at $0.76 per share on revenue of $3.37 million. •...
Via
Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
↗
March 20, 2022
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...
Via
Benzinga
Here's Why Marinus Pharmaceuticals Shares Are Moving
↗
March 18, 2022
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shares are trading higher by 25.0% at $10.72 after the company announced the FDA has approved ZTALMY oral suspension for the...
Via
Benzinga
Preview: Marinus Pharmaceuticals's Earnings
↗
March 18, 2022
Marinus Pharmaceuticals (NASDAQ:MRNS) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement....
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
March 02, 2022
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
↗
March 02, 2022
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
February 25, 2022
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week...
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
↗
February 23, 2022
Gainers Tenneco Inc. (NYSE: TEN) shares jumped 94.1% to $19.38 after the company announced it will be acquired by Apollo Funds. Tenneco also reported a Q4 loss of $0.11 per share...
Via
Benzinga
63 Biggest Movers From Yesterday
↗
February 24, 2022
Gainers Tenneco Inc. (NYSE: TEN) shares surged 93.9% to close at $19.35 on Wednesday after the company announced it will be acquired by Apollo Funds. Tenneco also reported a...
Via
Benzinga
Nervous Markets Rebound As Ukraine Tensions Fade
↗
February 23, 2022
U.S. President Joe Biden said Russia had started to invade Ukraine and announced steps targeting Russia’s sale of sovereign debt abroad, its elites and a pair of banks.
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 23, 2022
Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at...
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
↗
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.